Figure 1 | Scientific Reports

Figure 1

From: Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer

Figure 1The alternative text for this image may have been generated using AI.

Fibroblast growth factor receptor (FGFR) alterations in breast cancer patient-derived xenografts (PDXs). (a) FGFR expression and genomic alterations from 22 PDXs generated from 21 patients. (b) Relative protein expression of breast cancer PDXs determined by reverse phase protein array (RPPA). (c) Relative FGFR1-4 mRNA expression in patient samples and matching PDX models. RNA expression is presented in log2-normalized reads per kilobase million (RPKM). A 2-sided paired Student t test was used to calculate P-values. (d) The correlation of expression between FGFR genes in patient samples and those in matching PDX models is shown. RNA expression is presented in log2-normalized RPKM. The Pearson correlation coefficient (r) was used to measure the statistical association between 2 variables.

Back to article page